Demant is a Danish hearing-healthcare leader (Oticon hearing aids, plus diagnostics and hearing-care retail), one of a handful of global players in a structurally growing, demographics-driven oligopoly. Adjusted ROIC of ~10% and +DKK 559M economic profit reflect a solid but not exceptional franchise net of its retail/diagnostics mix.
The equity at DKK 243 embeds ~6.7% perpetual growth (reverse-DCF), and the balance sheet carries meaningful net debt (DKK 19.7B) with currently negative free cash flow (acquisitions/buybacks). Quality and demographics are real; the valuation is full and the leverage/FCF bear watching.
Bridging adjusted NOPAT through DKK 19.7B net debt, reverse-DCF fair value runs DKK 92–116 across scenarios — well below the DKK 243 price (~6.7% implied growth). The hearing-aid product cycle and premium positioning support a premium, but the equity is fully valued.
Base DKK 245 (flat); bull DKK 300 (a strong product cycle plus margin expansion and deleveraging); bear DKK 190 (product-cycle softness or consumer/leverage pressure).
At today’s enterprise value the constant-ROIC reverse-DCF maxes out: even at its sustainable-growth ceiling (~9.4%, limited by ROIC 10% ≈ WACC 8%) it cannot reach the current EV. No-growth value is DKK 92/share (37% of price); the market prices in growth and/or a higher ROIC than booked — richly valued on this lens. Read the sensitivity grid.
| Scenario | 24m target | Impl. g | Upside | Prob. | Driver |
|---|---|---|---|---|---|
| Bull | DKK 300 | ≥9% | +19% | 30% | Strong product cycle + margin + deleveraging |
| Base | DKK 245 | ≥9% | -2% | 45% | Full: ~6.7% implied growth |
| Bear | DKK 190 | ≥9% | -24% | 25% | Product-cycle softness or leverage pressure |
| Prob-weighted | DKK 248 | — | -1% | 100% | Scenario-weighted expected value |
| WACC \ g | 0% | 3% | 5% | 8% | 10% | 15% |
|---|---|---|---|---|---|---|
| 6.50% | 156 | 173 | 185 | 203 | 215 | 248 |
| 7.25% | 119 | 131 | 138 | 150 | 158 | 177 |
| 8.00% (base) | 92 | 100 | 105 | 112 | 116 | 126 |
| 8.75% | 72 | 76 | 79 | 83 | 85 | 88 |
| 9.50% | 56 | 58 | 59 | 60 | 60 | 58 |
Green = fair value above the current price of DKK 251.20. The reverse-DCF conclusion is dominated by WACC and growth — see the whole surface, not a single fair value.
⤓ Download the full model (.xlsx) — formula-driven sheets; flex the blue input cells and the model cascades in Excel.
A global hearing-aid oligopoly with premium Oticon positioning and pricing power.
An ageing population structurally expands hearing-care demand.
New premium hearing-aid platforms drive share and average selling prices.
Owned hearing-care retail/diagnostics captures more of the value chain.
Consistent share repurchase supports per-share metrics.
Demant is a quality hearing-healthcare oligopolist at a full price with leverage and negative current free cash flow. HOLD, medium conviction; base target DKK 245 (flat).
A strong product cycle plus deleveraging/FCF recovery is the upside; leverage and competition are the principal risks.
Every adjustment traces to the cited note/page in the source filing — click to open it there. Source reports archived locally.
NOPAT adjustments: Not available from structured data
Company add-backs we reject: Not available without footnote extraction
Pages read — FY: — · Q: —
How the mttssn view has evolved — each prior dated note is preserved.